Nm23 and HER2/neu gene expression and prognostic significance in urothelial carcinomas of the bladder

Aim: This study aimed to investigate the expressions of Nm23-H1 and HER2/neu in Turkish cases of urothelial carcinomas of bladder and to examine their associations with prognostic parameters. Urothelial carcinoma of the bladder is one of the most prevalent cancers worldwide. Nm23-H1 and HER2/neu expressions have been previously studied in urothelial carcinomas. Despite the availability of many reports in the literature, the prognostic significance of these expressions remains unclear. Materials and Methods: Fifty cases of urothelial carcinoma of the bladder treated with radical cystectomy were retrospectively reviewed. The tumor specimens were evaluated by immunohistochemistry using Nm23-H1 and HER2/neu antibodies. Results: Immunohistochemically, Nm23-H1 and HER2/neu expressions were present in 80% and 18% of cases and associated with pathological stage (p=0.025 and p=0.023, respectively). Conclusion: Both antibodies were noted in patients with advanced stage cancer, which can adversely affect prognosis in infiltrative urothelial carcinomas of the bladder. HER2/neu may be a target for therapy

PDF

___

1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424.
2. Zeegers MP, Kellen E, Buntinx F, et al. The association between smoking, beverage consumption, diet and bladder cancer: a systematic literature review. World J Urol 2004;21:392-401.
3. Kirkali Z, Chan T, Manoharan M, et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 2005;66:4-34.
4. Moch H, Cubilla AL, Humphrey PA, et al. The 2016 WHO classification of tumours of the urinary system and male genital organs—part A: renal, penile, and testicular tumours. Eur Urol 2016;70:93-105.
5. Shiina H, Igawa M, Nagami H, et al. Immunohistochemical analysis of proliferating cell nuclear antigen, p53 protein and nm23 protein, and nuclear DNA content in transitional cell carcinoma of the bladder. Cancer 1996;78:1762-74.
6. Steeg PS, Bevilacqua G, Kopper L, et al. Evidence for a novel gene associated with low tumor metastatic potential. JNCI 1988;80:200-4.
7. Rosengard AM, Krutzsch HC, Shearn A, et al. Reduced Nm23/Awd protein in tumour metastasis and aberrant Drosophila development. Nature 1989;342:177-80.
8. Hansel DE, Swain E, Dreicer R, et al. HER2 overexpression and amplification in urothelial carcinoma of the bladder is associated with MYC coamplification in a subset of cases. Am J Clin Pathol 2008;130:274-81.
9. El Ochi MR, Oukabli M, Bouaiti E, et al. Expression of human epidermal growth factor receptor 2 in bladder urothelial carcinoma. BMC clinical pathology 2017;17:3.
10. Ceylan O , Ozmen S . Prognostic Significance of HER2 Expression in Gastric Cancer. Black Sea Journal of Health Science 2021;4:52-57
11. Kumar V, Abbas AK, Fausto N, et al. Robbins and Cotran pathologic basis of disease, professional edition e-book: Elsevier health sciences 2014.
12. Ceylan O, Karabulut I. Importance of cytokeratin-20 expression in papillary urothelial neoplasia. Cukurova Med J 2020; 45:1326-1332
13. Mhawech-Fauceglia P, Cheney RT, Schwaller J. Genetic alterations in urothelial bladder carcinoma: an updated review. Cancer 2006;106:1205-16.
14. Kadlubar FF, Badawi AF. Genetic susceptibility and carcinogen-DNA adduct formation in human urinary bladder carcinogenesis. Toxicol Lett 1995;82:627-32.
15. Lapham RL, Grignon D, Ro JY, editors. Pathologic prognostic parameters in bladder urothelial biopsy, transurethral resection, and cystectomy specimens. Semin Diagn Pathol 1997.
16. Lipponen P, Eskelinen M. Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erb B-2, p53) expression and long-term prognosis. Br J Cancer 1994;69:1120-5.
17. Bos JL. Ras oncogenes in human cancer: a review. Cancer Res 1989;49:4682-9.
18. Khaled HM, Bahnassy AA, Raafat AA, et al. Clinical significance of altered nm23-H1, EGFR, RB and p53 expression in bilharzial bladder cancer. BMC cancer 2009;9:32.
19. Simon R, Struckmann K, Schraml P, et al. Amplification pattern of 12q13-q15 genes (MDM2, CDK4, GLI) in urinary bladder cancer. Oncogene 2002;21:2476-83.
20. Leone A, Flatow U, King CR, et al. Reduced tumor incidence, metastatic potential, and cytokine responsiveness of nm3-transfected melanoma cells. Cell 1991;65:25-35.
21. Bertheau P, De La Rosa A, Steeg PS, et al. NM23 protein in neoplastic and nonneoplastic thyroid tissues. Am J Pathol 1994;145:26.
22. Lacombe M-L, Sastre-Garau X, Lascu I, et al. Overexpression of nucleoside diphosphate kinase (Nm23) in solid tumours. Eur J Cancer Clin Oncol 1991;27:1302-7.
23. Yokoyama A, Okabe-Kado J, Wakimoto N, et al. Evaluation by multivariate analysis of the differentiation inhibitory factor nm23 as a prognostic factor in acute myelogenous leukemia and application to other hematologic malignancies. Blood, Comparative Study 1998;91:1845-51.
24. Tomita M, Ayabe T, Matsuzaki Y, et al. Expression of nm23-H1 gene product in esophageal squamous cell carcinoma and its association with vessel invasion and survival. BMC cancer 2001;1:1-6.
25. Kapitanovic S, Spaventi R, Vujsic S, et al. nm23-H1 gene expression in ovarian tumors--a potential tumor marker. Anticancer Res 1995;15:587-90.
26. Dursun A, Akyurek N, Gunel N, et al. Prognostic implication of nm23-H1 expression in colorectal carcinomas. Pathology 2002;34:427-32.
27. Kanayama Ho, Takigazva H, Kagazva S. Analysis of nm23 gene expressions in human bladder and renal cancers. Int J Urol 1994;1:324-31.
28. Chow N-H, Liu H-S, Chan S-H. The role of nm23-H1 in the progression of transitional cell bladder cancer. Clin Cancer Res 2000;6:3595-9.
29. Nakopoulou L, Constandinides C, Tzonou A, et al. Dimopoulos C. Immunohistochemical evaluation of nm23-H1 gene product in transitional cell carcinoma of the bladder. Histopathology 1996;28:429-35.
30. Kuo J, Chiang H, Chen K, et al. Immunohistochemical analysis of nm23-H1 protein in bladder cancer. Zhonghua yi xue za zhi. Chin Med J 1999;62:411-7.
31. Lönn U, Lönn S, Friberg S, et al. Prognostic value of amplification of c-erb-B2 in bladder carcinoma. Clin Cancer Res 1995;1:1189-94.
32. Jimenez RE, Hussain M, Bianco FJ, et al. Her-2/ neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors. Clin Cancer Res 2001;7:2440-7.
33. Gorgoulis VG, Barbatis C, Poulias I, et al. Molecular and immunohistochemical evaluation of epidermal growth factor receptor and c-erb-B-2 gene product in transitional cell carcinomas of the urinary bladder: a study in Greek patients. Mod Pathol 1995;8:758-64.
34. Krüger S, Weitsch G, Büttner H, et al. Overexpression of CerbB2 oncoprotein in muscle-invasive bladder carcinoma: relationship with gene amplification, clinicopathological parameters and prognostic outcome. Int J Oncol 2002;21:981-7.
35. Miyamoto H, Kubota Y, Noguchi S, et al. CERBB2 gene amplification as a prognostic marker in human bladder cancer. Urology 2000;55:679-83.
36. Coogan CL, Estrada CR, Kapur S, et al. HER-2/neu protein overexpression and gene amplification in human transitional cell carcinoma of the bladder. Urology 2004;63:786-90.